EMERGING TECHNOLOGY AND INNOVATION

The Emerging Technology and Innovation team complements therapeutic area-specific external research efforts by providing distinct geographic coverage plus access to novel pathways and new therapeutic modalities. We specialize in connecting partners to Lilly expertise and deploying flexible funding models. The team is comprised of experienced drug discovery and development scientists based in Cambridge, Mass. (external research hub established 2016), Indianapolis and Europe, with additional members in Japan.

New opportunities of interest include pan-therapeutic and adjacent disease areas (as well as added support for Lilly’s core therapeutic areas). We are committed to collaboration with premier universities, investigators and companies around the world to advance innovation, enhance Lilly’s pipeline and improve patient outcomes.

Our greatest interests lie in the following areas:

**Novel Biologic Pathways:**
Emphasis on those with multi-therapeutic area potential.
- Examples include: MicroRNA, exosome biology, epigenetics

**Adjacent Disease Areas:**
- Examples include: Fibrosis, kidney disease, vascular disease, other disorders of immune function, broader neurologic conditions

**Disruptive Technologies:**
- New therapeutic modalities (including, but not limited to, oligonucleotide-based approaches, gene editing, gene therapy, microbiome, cell-based approaches)
- Novel approaches to “drug” difficult targets (e.g., cell-penetrant peptide platforms)
Alternative Funding and Partnering Models:
This team has expertise in—and access to—flexible funding models for advancing exciting science.

- Strategic limited partnerships in world-class venture funds. These funds work with scientific and business leaders to advance breakthrough innovation. A key strategy involves early development funding and co-funding opportunities (emphasis on leveraging Lilly’s Chorus* organization)
- Direct equity investments in selected biotechnology companies
- “Build-to-buy” investments
- Other “shared-risk” drug discovery and early development relationships

*Chorus is a fully integrated early stage drug development team whose scope includes IND-enabling preclinical studies through Phase 2 development. Chorus specializes in delivery of rapid, efficient and cost-effective clinical proof-of-concept results. The team has extensive experience in developing externally derived molecules in partnership with selected VC firms (including HealthCare Ventures, TVM Capital, Atlas Ventures).